Reata Pharmaceuticals Files for Proposed Public Offering with SEC

Reata Pharmaceuticals, a clinical-stage biopharmaceutical company, said Tuesday it has filed with the U.S. Securities and Exchange Commission for a proposed underwritten public offering of shares of its common stock.

The company said it will use the net proceeds from the offering to advance the development of its lead product candidate, bardoxolone methyl, as well as its additional lead product candidate omaveloxolone, and to provide funds for working capital and other general purposes, including clinical trials and preclinical studies.

Leave a Comment